Algorae Pharmaceuticals Discloses Final Interests of Departing Director

An update from Living Cell Technologies ( (AU:1AI) ) is now available.

Algorae Pharmaceuticals has announced that director Bradley Latham has ceased to be a director of the company as of 10 March 2026. The company disclosed his final interests, including 20,000,000 ordinary shares, multiple tranches of performance rights and 4,000,000 unlisted options exercisable at a specified price and expiry, clarifying his remaining equity exposure for investors and regulators.

The notice confirms that Latham holds no relevant interests in securities through other registered holders and has no interests in related contracts. This formal update, lodged under ASX listing rules, completes the regulatory record of his equity position at departure and provides transparency to shareholders regarding changes in the company’s board and incentive arrangements.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited is an Australian biotechnology company focused on developing pharmaceutical products. The company operates in the life sciences sector, with a capital structure that includes ordinary shares, performance rights and unlisted options issued to key personnel as part of its incentive and compensation framework.

YTD Price Performance: 14.29%

Average Trading Volume: 1,464,938

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$27.41M

For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.